PA
CRSP icon

Parallel Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Parallel Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.7K Buy
1,131
+546
+93% +$28.8K ﹤0.01% 2002
2026
Q1 		$27.9K Sell
585
-34
-5% -$1.79K ﹤0.01% 2317
2025
Q4 		$32.5K Buy
619
+30
+5% +$1.8K ﹤0.01% 2070
2025
Q3 		$38.2K Buy
589
+51
+9% +$2.93K ﹤0.01% 1924
2025
Q2 		$26.2K Buy
538
+31
+6% +$1.2K ﹤0.01% 2065
2025
Q1 		$17.2K Buy
507
+67
+15% +$2.84K ﹤0.01% 2211
2024
Q4 		$17.3K Hold
440
– – ﹤0.01% 2204
2024
Q3 		$20.7K Sell
440
-399
-48% -$20.2K ﹤0.01% 2080
2024
Q2 		$45.3K Buy
839
+96
+13% +$5.55K ﹤0.01% 1582
2024
Q1 		$50.6K Buy
743
+391
+111% +$28K ﹤0.01% 1491
2023
Q4 		$22K Buy
352
+139
+65% +$7.68K ﹤0.01% 1874
2023
Q3 		$9.67K Buy
213
+20
+10% +$1.03K ﹤0.01% 2217
2023
Q2 		$10.8K Hold
193
– – ﹤0.01% 2138
2023
Q1 		$8.73K Sell
193
-47
-20% -$2.28K ﹤0.01% 2193
2022
Q4 		$9.76K Sell
240
-74
-24% -$3.93K ﹤0.01% 2034
2022
Q3 		$21K Sell
314
-3
-0.9% -$217 ﹤0.01% 1661
2022
Q2 		$19K Buy
317
+13
+4% +$764 ﹤0.01% 1685
2022
Q1 		$19K Sell
304
-100
-25% -$6.28K ﹤0.01% 1742
2021
Q4 		$31K Buy
404
+74
+22% +$6.46K ﹤0.01% 1573
2021
Q3 		$37K Sell
330
-103
-24% -$12.9K ﹤0.01% 1416
2021
Q2 		$70K Buy
433
+125
+41% +$15.2K ﹤0.01% 1078
2021
Q1 		$38K Buy
308
+63
+26% +$9.51K ﹤0.01% 1302
2020
Q4 		$38K Buy
+245
New +$29K ﹤0.01% 1213
2020
Q2 		– Sell
-557
Closed -$23K – 2480
2020
Q1 		$23K Buy
557
+198
+55% +$10.2K ﹤0.01% 1250
2019
Q4 		$22K Hold
359
– – ﹤0.01% 1352
2019
Q3 		$15K Hold
359
– – ﹤0.01% 1489
2019
Q2 		$17K Buy
+359
New +$14.3K ﹤0.01% 1355
2018
Q3 		– Sell
-200
Closed -$11K – 2231
2018
Q2 		$11K Buy
+200
New +$11.4K ﹤0.01% 1295

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Parallel Advisors's CRSP Position: Q2 2026 in Review

Parallel Advisors increased its CRISPR Therapeutics (CRSP) stake by 93% in Q2 2026, buying an estimated $28.8K and bringing the position to 1,131 shares worth $61.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Parallel Advisors first reported a position in CRSP in Q2 2018 and has held it in 28 quarters since. The position peaked at $70K in Q2 2021. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Parallel Advisors held 1,131 shares of CRISPR Therapeutics worth $61.7K as of Q2 2026.
  • Parallel Advisors bought 546 CRISPR Therapeutics shares in Q2 2026, an estimated $28.8K.
  • CRISPR Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2002 holding.
  • Parallel Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 28 quarters since.
  • Parallel Advisors's CRISPR Therapeutics position peaked at $70K in Q2 2021.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.